



March 18, 2022

To All OSPHL SARS-CoV-2 Sequencing Clients,

Beginning April 4, 2022, the Oregon State Public Health Laboratory (OSPHL) SARS-CoV-2 sequencing team will implement changes to the laboratory result reports. Please forward this message to your colleagues who may need this information.

### **What is changing?**

The following report elements will be changed:

- Pango Lineage: OSPHL will begin reporting all Pango lineage designations on result reports. To date, OSPHL has only reported the designation when the lineage is a variant of interest or concern.
- NCBI Sequence Read Archive (SRA): Field title will be changed to “NCBI GenBank Accession ID.”
- Various report comment changes

The following report element will be added:

- Pango Version: The version of Pango lineage classifications is provided to help submitters track changes in variant classifications over time. This information helps submitters understand the classification assigned at the time of result report.

The following report elements will be removed:

- SARS-CoV-2 Variant: Used to specify whether the variant detected was classified as a variant of interest or concern. These designations change over time, making this information less pertinent.
- Substitution of Therapeutic Concern: CDC no longer publishes a list of these substitutions.

### **Why these changes?**

These changes are being made as part of OSPHL’s continued quality improvement efforts and to simplify some result report elements.

OSPHL continues to perform sequencing in alignment with the established [Criteria for Requesting COVID-19 Sequencing at OSPHL](#).

Please contact Shane Sevey, Virology/Immunology Section Manager, with questions at 503-693-4154 or [shane.a.sevey@dhsosha.state.or.us](mailto:shane.a.sevey@dhsosha.state.or.us).

Sincerely,

John Fontana, PhD, (HCLD) ABB  
Director, OSPHL

Shane Sevey  
Manager, OSPHL Virology/Immunology